Is it true that a box of Vebreltinib costs 8,000 yuan?

As a domestic innovative MET inhibitor, vebreltinib/vebreltinib's indications clearly point to a specific molecular type of patient group. Innon-small cell lung cancer,MET exon 14 skipping is an important type of driver gene mutation. These patients often have limited response to traditional treatments, so they require targeted drug intervention. Bricitinib provides an effective treatment option for this population. In addition to lung cancer indications, the drug is also approved for the treatment of adult patients with IDH-mutant astrocytoma and some glioblastoma who have failed previous treatments and have PTPRZ1-MET fusion genes. Since these brain tumors are difficult to treat and have a poor prognosis, the emergence of bricitinib has brought new treatment options to patients.

As for the price issue, the market price of bricitinib is indeed relatively high after it was launched in the country. The common specifications are 100mg*60 tablets, and the price per box is about 7,000 yuan. Therefore, the statement "8,000 yuan per box" is not completely fictitious, but is related to market fluctuations and differences in different channels. Although the price of a single box seems expensive, since it has been included in the scope of medical insurance reimbursement, the actual out-of-pocket amount paid by patients will be significantly reduced, which alleviates the treatment burden to a certain extent. Price issues are common in the field of anti-cancer drugs, and the intervention of medical insurance is an effective way to resolve this contradiction.

It is worth noting that drug pricing is not only related to production costs, but also affected by R&D investment, marketing and clinical demand. As an innovative drug independently developed in China, the price of bricitinib is still far lower than that of some similar imported targeted drugs. At the policy level, the country also continues to lower the accessibility threshold of anti-cancer drugs through negotiations and catalog updates. For patients, the most important thing is to choose drugs rationally under the guidance of a doctor based on their own genetic test results, rather than just focusing on the price of a single box.

Reference materials:https://www.asymbio.com.cn/